Rheumatology

Back to articles

Infection risk differs among biologic agents for rheumatoid arthritis

KEY POINT

For patients with rheumatoid arthritis (RA) with prior biologic exposure, the risk of hospitalized infection was higher with etanercept (Enbrel—Amgen), infliximab (Remicade—Janssen Biotech), and rituximab (Rituxan—Genentech, Biogen) compared with abatacept (Orencia—Bristol-Myers Squibb), according to an observational study published in Arthritis & Rheumatology.